Covagen's Uniqueness

Covagen is a clinical stage company that develops bispecific FynomAbs by fusing its human Fynomer® binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy. Our current pipeline is focussed on the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy.

More About Us >>

Pipeline Highlights

Covagen is developing COVA322 for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. COVA322 is a bispecific FynomAb® inhibiting TNF and IL-17A. COVA322 is currently investigated in a Phase Ib/IIa clinical trial.

More About COVA322 >>

News & Events

Covagen Initiates Phase Ib/IIa Study of Bispecific anti-TNF/IL-17A FynomAb COVA322
May 5, 2014: Covagen today announced it has initiated a Phase Ib/IIa study with COVA322, a bispecific TNF/IL-17A inhibitor. COVA322 is Covagen’s lead bispecific FynomAb developed for treatment of patients with rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases.
Covagen Adds Baxter Ventures as Investor
Feb 19, 2014: Covagen today announced it has added Baxter Ventures as an investor in its Series B financing round raising the total to CHF 44.9 million.
Covagen Secures CHF 42 Million in Series B Financing
Covagen has secured CHF 42 million in a tranched Series B financing with an option to obtain an additional CHF 14 million.

More News & Events >>